ELAN vs. BPMC, CYTK, ITCI, JAZZ, IONS, CERE, ASND, APLS, OGN, and BBIO
Should you be buying Elanco Animal Health stock or one of its competitors? The main competitors of Elanco Animal Health include Blueprint Medicines (BPMC), Cytokinetics (CYTK), Intra-Cellular Therapies (ITCI), Jazz Pharmaceuticals (JAZZ), Ionis Pharmaceuticals (IONS), Cerevel Therapeutics (CERE), Ascendis Pharma A/S (ASND), Apellis Pharmaceuticals (APLS), Organon & Co. (OGN), and BridgeBio Pharma (BBIO). These companies are all part of the "pharmaceutical preparations" industry.
Blueprint Medicines (NASDAQ:BPMC) and Elanco Animal Health (NYSE:ELAN) are both mid-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, community ranking, valuation, institutional ownership, dividends, media sentiment, profitability, earnings and risk.
Blueprint Medicines has a beta of 0.65, meaning that its share price is 35% less volatile than the S&P 500. Comparatively, Elanco Animal Health has a beta of 1.34, meaning that its share price is 34% more volatile than the S&P 500.
In the previous week, Blueprint Medicines had 43 more articles in the media than Elanco Animal Health. MarketBeat recorded 59 mentions for Blueprint Medicines and 16 mentions for Elanco Animal Health. Blueprint Medicines' average media sentiment score of 0.81 beat Elanco Animal Health's score of 0.55 indicating that Elanco Animal Health is being referred to more favorably in the news media.
Elanco Animal Health has a net margin of -27.87% compared to Elanco Animal Health's net margin of -102.15%. Blueprint Medicines' return on equity of 6.44% beat Elanco Animal Health's return on equity.
Blueprint Medicines has higher earnings, but lower revenue than Elanco Animal Health. Blueprint Medicines is trading at a lower price-to-earnings ratio than Elanco Animal Health, indicating that it is currently the more affordable of the two stocks.
Blueprint Medicines currently has a consensus price target of $100.31, suggesting a potential downside of 7.78%. Elanco Animal Health has a consensus price target of $16.71, suggesting a potential downside of 0.98%. Given Blueprint Medicines' stronger consensus rating and higher possible upside, analysts clearly believe Elanco Animal Health is more favorable than Blueprint Medicines.
Blueprint Medicines received 388 more outperform votes than Elanco Animal Health when rated by MarketBeat users. Likewise, 67.80% of users gave Blueprint Medicines an outperform vote while only 54.17% of users gave Elanco Animal Health an outperform vote.
97.5% of Elanco Animal Health shares are held by institutional investors. 3.9% of Blueprint Medicines shares are held by company insiders. Comparatively, 0.6% of Elanco Animal Health shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Summary
Elanco Animal Health beats Blueprint Medicines on 11 of the 19 factors compared between the two stocks.
Get Elanco Animal Health News Delivered to You Automatically
Sign up to receive the latest news and ratings for ELAN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ELAN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Elanco Animal Health Competitors List
Related Companies and Tools
